Scarica l'app Stockscreener
8.96
4.58%
-0.43
Precedente Chiudi:
$9.39
Aprire:
$9.23
Volume 24 ore:
1,302
Relative Volume:
0.24
Capitalizzazione di mercato:
$43.42M
Reddito:
$2.61M
Utile/perdita netta:
$1.69M
Rapporto P/E:
29.84
EPS:
0.3003
Flusso di cassa netto:
-
1 W Prestazione:
-0.44%
1M Prestazione:
+15.76%
6M Prestazione:
+12.70%
1 anno Prestazione:
-6.57%
Intervallo 1D:
$8.76
$9.345
Intervallo di 1 settimana:
$8.68
$9.75
Portata 52W:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Nome
Daxor Corporation
Settore
Industria
Telefono
212-330-8500
Indirizzo
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Confronta DXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
9.345 | 43.42M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
537.77 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
170.10 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.53 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.21 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.97 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-16 | Iniziato | Ascendiant Capital Markets | Buy |
Daxor Corporation Borsa (DXR) Ultime notizie
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - The Globe and Mail
(DXR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
(DXR) Proactive Strategies - news.stocktradersdaily.com
(DXR) Investment Analysis - news.stocktradersdaily.com
Daxor announces new findings from Duke University on BVA - TipRanks
Daxor (DXR) Highlights Key Heart Failure Study Results | DXR Sto - GuruFocus
Daxor Announces Duke University Study on Blood Volume - GlobeNewswire
Duke Research Reveals 40% of Heart Failure Patients Misdiagnosed with Anemia, Study Shows - Stock Titan
Daxor (DXR) Expands Diagnostic Solutions Across U.S. Healthcare Systems | DXR Stock News - GuruFocus
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems - GlobeNewswire
Daxor announces opening of new BVA program at Florida center - TipRanks
Daxor (DXR) Launches Advanced BVA Program in Tampa Bay Healthcare Center | DXR Stock News - GuruFocus
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology - GlobeNewswire
Renaissance Technologies LLC Has $214,000 Stock Holdings in Daxor Co. (NASDAQ:DXR) - Defense World
Daxor announces expansion of BVA capabilities in three new hospitals - TipRanks
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Part - GuruFocus
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Partnerships | DXR Stock News - GuruFocus
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance - GlobeNewswire
NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) Head-To-Head Comparison - Defense World
Daxor Corporation Secures Funding for Blood Volume Analyzer Study - Medical Product Outsourcing
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
Critical Analysis: Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) - The AM Reporter
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - The Manila Times
Daxor Corporation to Exhibit at the 45th International - GlobeNewswire
Revolutionary Blood Volume Analysis: How Daxor's 98% Accurate Tech is Transforming Heart and Lung Care - Stock Titan
Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) Head to Head Review - Defense World
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Azioni (DXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Daxor Corporation Azioni (DXR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Michel Robert J | Chief Financial Officer |
Mar 10 '25 |
Buy |
8.00 |
1,000 |
8,000 |
17,050 |
| Feldschuh Michael Richard | Chief Executive Officer |
Mar 10 '25 |
Buy |
7.68 |
3,360 |
25,805 |
210,852 |
0.12%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):